Medrx Co. Ltd. | Cash Flow

Fiscal year is January-December. All values JPY Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
616,644.00
1,012,115.00
874,026.00
1,254,618.00
880,044.00
1,265,227
Depreciation, Depletion & Amortization
28,257.00
52,460.00
76,129.00
57,556.00
59,171.00
39,911
Other Funds
-
-
4,800.00
22,628.00
-
2,326
Funds from Operations
612,314.00
926,381.00
774,104.00
1,217,447.00
909,790.00
1,227,645
Changes in Working Capital
977.00
5,431.00
14,956.00
2,446.00
55,470.00
33,202
Net Operating Cash Flow
613,291.00
931,812.00
789,060.00
1,215,001.00
854,320.00
1,260,847
Capital Expenditures
70,394.00
112,471.00
38,741.00
6,877.00
50,486.00
Purchase/Sale of Investments
100,000.00
-
-
416,883.00
611,000.00
Net Investing Cash Flow
192,444.00
119,821.00
43,641.00
410,006.00
661,486.00
Issuance/Reduction of Debt, Net
305,843.00
99,000.00
-
631,800.00
-
Net Financing Cash Flow
4,545,171.00
99,000.00
113,650.00
1,385,931.00
-
Net Change in Cash
3,771,766.00
1,156,827.00
717,459.00
577,078.00
1,513,142.00
Free Cash Flow
682,281.00
1,042,073.00
827,801.00
1,221,878.00
904,806.00
Change in Capital Stock
4,851,014.00
-
108,850.00
731,503.00
-
Exchange Rate Effect
32,330.00
6,194.00
1,592.00
3,858.00
2,664.00
Other Uses
22,050.00
7,350.00
4,900.00
-
-

About Medrx Co.

View Profile
Address
431-7 Nishiyama
Higashikagawa Kagawa 769
Japan
Employees -
Website http://www.medrx.co.jp
Updated 07/08/2019
Medrx Co. Ltd. engages in the business of pharmaceutical drug development based on the transdermal absorption. It develops new value-added medicines by the drug formulation technology based on ILTS (Ionic Liquid Transdermal System), a unique technologies using ionic liquid. The company was founded by Masayoshi Matsumura on January 15, 2002 and is headquartered in Higashikagawa, Japan.